Clinical investigation 101
This article was originally published in The Gray Sheet
Executive Summary
Agency's Office of Critical Path Programs will launch a three-day training course for clinical investigators in November, designed to improve the quality and efficiency of trials and improve investigators' understanding of the scientific, ethical and regulatory issues involved in clinical research. Lectures and discussions will be conducted by more than 20 senior staff from FDA's device, drug and biologics centers
You may also be interested in...
Regulatory News In Brief
Investigator training: A three-day training course for clinical investigators on scientific, ethical and regulatory aspects of trials will be held Nov. 16-18 in Silver Spring, Md. (1"The Gray Sheet" May 11, 2009). The event is co-sponsored by FDA and the FDA/Duke University Clinical Trials Transformation Initiative. Participants must register at 2https://www.trialstransformation.org/course-registration by Nov. 2. Rachel Behrman, director of FDA's Office of Critical Path Programs, will run a session on FDA regulations and investigators' responsibilities in clinical trials. Cardiovascular Devices Division Director Bram Zuckerman will discuss clinical trial design issues for devices. Microbiology Devices Director Sally Hojvat will discuss diagnostic and combination product trial questions, according to a preliminary 3agenda
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.